Keypoints:
• The evolution of treatment options for neuroendocrine tumors
• Insights into the CABINET study design and results
• Sequencing treatment options for patients with neuroendocrine tumors
• Side effects and management strategies for cabozantinib
• The importance of personalized treatment approaches in oncology
In this episode of the Oncology Brothers podcast, we discussed the recent FDA approval of cabozantinib for neuroendocrine tumors based on the findings from the CABINET study. Drs. Rahul and Rohit Gosain were joined by Dr. Aman Chauhan, a medical oncologist specializing in neuroendocrine tumors at Sylvester Comprehensive Cancer Center in Miami.
We started by discussing the evolving landscape of neuroendocrine tumors, which were once considered rare but are now increasingly prevalent due to improved patient survival rates. Dr. Chauhan provided a comprehensive overview of the CABINET study, highlighting its design, which included both pancreatic and extra-pancreatic neuroendocrine tumors, and the significance of including various grades of tumors in the research.
One of the key takeaways from our discussion is the impressive median progression-free survival (PFS) benefit observed with cabozantinib compared to placebo, particularly in heavily pre-treated patients. We also touched on the challenges of assessing overall survival in this patient population due to the indolent nature of neuroendocrine tumors.
Dr. Chauhan shared his insights on how he plans to incorporate cabozantinib into treatment sequences, emphasizing the need for a tailored approach based on individual patient characteristics. We also discussed the side effect profile of cabozantinib, noting that while it shares common TKI-related side effects, it can be better tolerated at lower doses.
As we wrapped up, Dr. Chauhan encouraged the oncology community to continue exploring inclusive trial designs and to focus on sequencing treatment options rather than solely seeking new therapies. This episode highlighted the exciting advancements in the management of neuroendocrine tumors and the importance of staying informed about new treatment options.
Thank you for joining us, and be sure to check out our other discussions on FDA approvals, toxicity management, and conference highlights. We are the Oncology Brothers!
Listen Podcast on Your Favourite Platform
